TLPPF

TELIX PHARM LTD by Telix Pharmaceutical Ltd. (TLPPF)

About TELIX PHARM LTD by Telix Pharmaceutical Ltd. (TLPPF)

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Details

Daily high

Daily low

Price at open

52 Week High

$24.85

52 Week Low

$8.90

Market cap

6.5B

Dividend yield

0.00%

Volume

20,010

Avg. volume

4,173

P/E ratio

193.27

TELIX PHARM LTD by Telix Pharmaceutical Ltd. News